StocksMedium•4 November 2026•
1 min read
Progyny Reports Record Q3 Results and Raises Full-Year 2026 Guidance
Key Facts
1Progyny achieved record revenue, net income, and Adjusted EBITDA during the third quarter.
2The company added 1.3 million new covered lives during its latest selling season, its highest ever.
3The company raised the midpoint of its full-year 2026 financial guidance ranges.
Progyny achieved record revenue, net income, and Adjusted EBITDA during the third quarter of 2026. GlobeNewswire reported that the company added 1.3 million new covered lives during its latest selling season, marking its highest level ever, and subsequently raised the midpoint of its full-year 2026 financial guidance ranges.
PGNY closed at $29.06 on November 3, 2026, ahead of the results which highlighted sustained growth in the client base. The company stated it had 607 fertility and family building clients as of September 30, 2026, up from 553 clients in the prior year period, supported by near 100% client retention rates.